Astellas Pharma (4503) FY2026 Q3 Earnings Report

Quick View

Executive Summary

For the nine months ended Q3, the Company returned to operating profitability due to higher revenue and the absence of the significant impairment loss recorded in the previous year. Revenue was ¥1.6013T (+10.2% YoY), Operating Income was ¥333.9B (compared with a ¥22.5B loss in the previous year), Profit Before Tax was ¥328.6B (compared with a ¥29.3B loss in the previous year), and Net Income attributable to owners of the parent was ¥248.0B (compared with a ¥24.1B loss in the previous year). The primary drivers of the increase in profit were growth in key strategic products, the containment of SG&A expenses and R&D expenses, and the rebound from the impairment loss of ¥181.1B recorded in the previous year period.

Factors Affecting Results

【Revenue】Revenue was ¥1.6013T, representing a 10.2% YoY increase. The five key strategic products—PADCEV, IZERVAY, VYLOY, VEOZAH, and XOSPATA—collectively drove revenue growth of more than ¥100.0B YoY and were the primary cause of double-digit growth.

【Profit and Loss】Operating Income turned from a ¥22.5B loss in the previous year period to ¥333.9B in profit. SG&A expenses were ¥625.6B, down 1.0% YoY, while R&D expenses were ¥218.9B, down 12.9% YoY, with cost containment contributing to the increase in profit. In addition, the impairment loss declined substantially from ¥181.1B in the previous year period to ¥22.7B in the current period, which was a significant factor in the improvement in earnings. This reduction in impairment losses is a temporary factor and must be evaluated separately from the improvement in recurring earnings power. The difference between Profit Before Tax and Net Income attributable to owners of the parent (¥248.0B) was due to income taxes of ¥80.6B, resulting in an effective tax rate of approximately 24.5%, with no particular divergence. In conclusion, the Company achieved both revenue and profit growth.

Segment Analysis

The Company operates as a single Pharmaceutical Business segment, and disclosure of operating profit and loss by segment has been omitted. By product, the five key strategic products—PADCEV, IZERVAY, VYLOY, VEOZAH, and XOSPATA—collectively drove revenue growth of more than ¥100.0B YoY and effectively functioned as the core business, lifting company-wide performance.

Key Financial Indicators

Profitability: ROE (annualized) was 18.7%, and Operating Margin was 20.9% (negative 1.5% in the previous year period)
Cash flow quality: Operating Cash Flow (OCF) / Net Income was 1.44x, and FCF was ¥310.8B
Investment efficiency: Capital expenditures were ¥41.1B versus depreciation and amortization of intangible assets of ¥144.2B, resulting in a capital expenditure / depreciation ratio of 0.28x
Financial soundness: Equity Ratio was 48.9% (45.3% in the previous year period), and the Current Ratio was 108.8%

Cash Flow Analysis

Operating Cash Flow was ¥356.8B, or 1.44x Net Income, indicating strong cash support for earnings. Investing Cash Flow was negative ¥46.0B, primarily due to capital expenditures of ¥41.1B and acquisitions of intangible assets of ¥24.6B. Financing Cash Flow was negative ¥246.6B, mainly reflecting dividend payments of ¥136.1B and a net decrease in bonds and borrowings (a ¥29.9B decrease in short-term debt and ¥62.4B in long-term repayments). FCF was ¥310.8B (OCF ¥356,771 million + Investing Cash Flow -¥45,980 million). Trade receivables increased by ¥145.2B from the beginning of the period and represented a ¥98.0B use of cash in OCF, which is a monitoring point for cash conversion. Cash generation is assessed as strong.

Earnings Quality

The difference between Profit Before Tax of ¥328.6B and Net Income attributable to owners of the parent of ¥248.0B was due to income taxes of ¥80.6B, with no particular temporary divergence. Other income was ¥25.4B (1.6% of Revenue), while other expenses were ¥35.8B (2.2% of Revenue), including an impairment loss of ¥22.7B. In the previous year period, other expenses were exceptionally high at ¥220.6B, primarily due to the impairment loss of ¥181.1B. OCF exceeded Net Income (1.44x), and accruals were negative, supporting an assessment that earnings quality is favorable. However, an impairment loss of ¥22.7B was still recorded in the current period, and the impairment risk associated with intangible assets and goodwill (together representing 41.3% of total assets) remains an ongoing point of concern.

Earnings Forecast and Guidance

The Q3 year-to-date progress rates against the full-year forecast (Revenue ¥2,100.0B, Operating Income ¥340.0B, Net Income ¥250.0B) were 76.3% for Revenue, 98.2% for Operating Income, and 99.2% for Net Income. Compared with standard progress of 75%, revenue was broadly in line with the standard level, while profit progress substantially exceeded it. The full-year forecast had already been revised upward during the current quarter (Revenue +¥70.0B, Core Operating Income +¥30.0B). The high level of profit progress reflects the rebound from the impairment loss recorded in the previous year period and the effects of cost containment. The occurrence of R&D expenses and SG&A expenses in Q4, as well as whether additional impairment losses are recorded, will be factors affecting the full-year outcome.

Shareholder Returns

The Q2 dividend was ¥39 per share. The full-year dividend forecast is ¥78, with no revision. The dividend Payout Ratio based on Net Income (an estimate calculated using Net Income attributable to owners of the parent of ¥248.0B and the actual Q2 dividend) is 28.5% (based on the calculation methodology determined by the Company). Share repurchases totaled ¥0.73B for the nine months ended Q3 and were small in scale, making dividends the core form of shareholder returns. Because the assessment is based solely on dividends, the term “Payout Ratio” is used. FCF of ¥310.8B substantially exceeded dividend payments of ¥136.1B, and considering the levels of cash and OCF, there is little concern regarding dividend sustainability.

Catalysts

【Short Term】Details of the full-year earnings outlook will be presented at the earnings briefing scheduled for February 4, 2026. The occurrence of R&D expenses and SG&A expenses in Q4, as well as foreign-exchange sensitivity to both yen appreciation and yen depreciation (as stated in the PDF materials: for each ¥1 movement, the impact for the U.S. dollar is approximately ¥2.0B on Revenue and approximately ¥0.5B on Core Operating Income, while the impact for the euro is approximately ¥0.9B on Revenue and approximately ¥0.4B on Core Operating Income), will be factors affecting performance.

【Long Term】Key areas of focus include the expansion of PADCEV indications (achievement of the primary endpoint in cisplatin-eligible MIBC), progress in Phase III trials for ASP3082 and ASP2138 following achievement of proof of concept (PoC), and progress on the SMT cost optimization plan targeting cumulative savings of ¥150.0B through FY2027.

Industry Benchmark (For Reference; Compiled by the Company)

Industry Benchmark (pharma)

Profitability and Returns

The Company demonstrates profitability substantially above the industry median and ranks at a relatively high level within an industry distribution containing many loss-making companies.

Growth and Capital Efficiency

The Company’s revenue growth rate substantially exceeded the industry median, which reflected negative growth, indicating relatively high growth within the industry.

※Source: Compiled by the Company

Risk Factors

1. Inventory and Working Capital Risk: Inventories increased by ¥32.7B from the beginning of the period to ¥330.0B, while trade receivables increased by ¥145.2B to ¥777.8B. The increase in working capital represented a total cash outflow of ¥113.9B in OCF, and the collection status of inventories and receivables will affect future cash-generating capacity.

2. Impairment Risk for Intangible Assets and Goodwill: Intangible assets of ¥1,052.0B and goodwill of ¥436.1B together account for 41.3% of total assets. Although the impairment loss recorded in the current period was ¥22.7B, down from ¥181.1B in the previous year period, additional impairment losses may arise depending on pipeline progress and changes in the competitive environment.

3. Short-Term Debt Refinancing Risk: Bonds and borrowings included in current liabilities amounted to ¥405.3B, exceeding cash and cash equivalents of ¥254.3B. Non-current bonds and borrowings decreased by ¥244.9B from the beginning of the period, resulting in a shorter-term debt structure; therefore, refinancing trends require monitoring.

Key Takeaways from the Earnings

1. The turnaround from an operating loss in the previous year period to Operating Income of ¥333.9B includes the temporary factor of the rebound from the significant impairment loss of ¥181.1B recorded in the previous year, in addition to revenue growth from key strategic products and cost containment. The improvement in recurring earnings power should be evaluated excluding this temporary factor.

2. Profit progress against the full-year forecast was high, at 98.2% for Operating Income and 99.2% for Net Income, and the Company also revised its full-year forecast upward during the current quarter. The R&D expense ratio declined to 13.7% from 17.3% in the previous year period. The balance between short-term margin improvement and medium- to long-term allocation of R&D investment will be a key focus going forward.

3. The Equity Ratio improved to 48.9%, and total bonds and borrowings decreased by ¥106.1B from the beginning of the period, strengthening the financial foundation. Meanwhile, trade receivables and inventories within current assets continued to increase, making the trend in cash conversion a key area of focus.

Theoretical Share Price (Reference Value)

Sensitivity: ¥1,147–¥1,213 at ±1% for the cost of equity, and ¥1,174–¥1,186 at ±0.1 for ω.

Notes:

• The impact on EPS of a ±¥5 movement from the assumed exchange rate (approximately ¥1.1 per share) is reflected in the bear/bull scenarios.
• Because Net Income progress against the full-year forecast (99%) exceeds the standard level (75%), forecast EPS has been adjusted upward within a range capped at +10% (because companies whose progress is ahead of schedule tend to exceed forecasts. In businesses with strong seasonality, the adjustment may be excessive).
• Net assets as of the end of the quarter are used (there is a timing difference relative to the full-year forecast).

(Calculation model: Residual Income Model (Ohlson type, explicit five-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee the future share price.)

---

This report is an earnings analysis document automatically generated through AI-integrated analysis of XBRL earnings summary data and PDF earnings presentation materials. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility and, where necessary, after consulting with a professional advisor.

---End of Report---

---

AI Financial Analysis

Executive Summary

Astellas delivered a decisive earnings recovery through FY2026 Q3, with strong sales growth, sharply lower impairment-related charges, and cash generation exceeding reported profit. Revenue increased 10.2% year on year to ¥1,601.3bn. Gross profit increased to ¥1,286.6bn, although the gross margin declined 92bp year on year to 80.3% as cost of sales grew faster than revenue. SG&A declined 1.0% year on year to ¥625.6bn, improving the SG&A-to-sales ratio by 42bp to 39.1%. R&D expense declined 12.9% to ¥218.9bn, lowering R&D intensity to 13.7% from 17.3% in the prior-year period. Operating income was ¥333.9bn, compared with an operating loss of ¥22.5bn a year earlier, and the operating margin improved to 20.9% from negative 1.5%. The principal driver of the turnaround was the reduction in other expenses to ¥35.8bn from ¥220.6bn, including impairment losses falling to ¥22.7bn from ¥181.1bn. Net income attributable to owners was ¥248.0bn, versus a ¥24.1bn loss in FY2025 Q3, producing basic EPS of ¥138.48. The effective tax rate was 24.5%, and the tax burden of 0.755 was within a normal range. Operating cash flow of ¥356.8bn exceeded net income by 44%, supporting the quality of the current-period earnings recovery. Free cash flow was ¥310.8bn after ¥41.1bn of capital expenditure, comfortably funding the ¥136.1bn dividend payment during the nine-month period. However, receivables increased by ¥145.2bn and inventory rose by ¥32.7bn from fiscal year-end, while reported inventory days of 287 remain a material working-capital and inventory-obsolescence concern. The balance sheet remains adequately capitalized, with an equity ratio improving to 48.9% from 45.3% at the prior-year Q3. Management's FY2026 forecasts imply that nine-month operating profit and net income have already reached 98.2% and 99.2%, respectively, of full-year guidance, materially ahead of the normal 75% seasonal progress rate. This creates scope for a strong full-year result but also means the Q4 profit run-rate implied by unchanged guidance is modest. The investment focus should be on the durability of revenue growth, normalization of impairment charges, execution against the development pipeline, the inventory position, and whether the guidance revision reflects sustainable operating momentum rather than primarily reduced exceptional costs.

Profitability Analysis

Annualized DuPont ROE is 18.7%, comprising a 15.5% net profit margin, 0.592x asset turnover, and 2.04x financial leverage. The strongest contributor to the return recovery is the margin rebound: annualized ROE had been negative in the prior-year period because the group reported net and operating losses. The annualized net margin of 15.5% is excellent by pharmaceutical-sector and general profitability benchmarks, while the 20.9% EBIT margin is also strong. Gross margin remained structurally high at 80.3%, consistent with a branded pharmaceutical portfolio, but was 92bp below the 81.3% prior-year level. The operating-margin expansion of approximately 2,240bp year on year was therefore not driven by gross-margin improvement. It was driven principally by a ¥184.8bn reduction in other expenses, including a ¥158.4bn reduction in impairment losses, together with ¥6.1bn lower SG&A and ¥32.5bn lower R&D. The reduction in exceptional impairment charges materially improves comparability, but the magnitude of the operating-income swing means the current-period margin should not be extrapolated solely as a recurring cost-efficiency gain. R&D intensity of 13.7% is below the 15-20% innovator-pharma reference range, reflecting the lower R&D expense in the period; the sustainability of earnings should be assessed alongside pipeline investment needs rather than treating lower R&D as an unambiguously positive margin lever. Financial leverage of 2.04x is moderate and reflects a 48.9% equity ratio, rather than aggressive balance-sheet leverage. Asset turnover of 0.592x is reasonable for an IP-intensive pharmaceutical group but is constrained by the large intangible-asset base. The interest burden of 0.984 indicates finance costs had only a limited effect on pre-tax earnings. The tax burden of 0.755 indicates that the conversion of pre-tax income to net income was normal. Overall, profitability is currently strong, but a meaningful portion of the year-on-year increase reflects the absence of the prior-period impairment burden.

Growth Assessment

Revenue growth of 10.2% to ¥1,601.3bn is a constructive underlying outcome and is more informative for operating momentum than the large profit rebound alone. Gross profit increased 9.0%, slightly below revenue growth, consistent with the modest gross-margin compression. SG&A fell 1.0% despite revenue growth, indicating favorable operating leverage in commercial and administrative spending. R&D expense decreased 12.9%, further supporting earnings growth but reducing R&D intensity to 13.7%. Operating profit of ¥333.9bn represents 98.2% of the ¥340.0bn full-year forecast, 23.2 percentage points above the standard 75% Q3 progress rate. Net income of ¥248.0bn represents 99.2% of the ¥250.0bn full-year forecast, 24.2 percentage points above the standard progress rate. Revenue progress is 76.3% of the ¥2,100.0bn full-year forecast, only 1.3 percentage points above the standard rate, suggesting the outperformance is much more pronounced in profit than in sales. The implied Q4 revenue needed to meet guidance is ¥498.7bn, while implied Q4 operating income is only ¥6.1bn and implied net income is ¥2.0bn. Accordingly, the forecast embeds either a conservative stance, anticipated Q4 expenses, or possible volatility in product, pipeline, or other-cost items. The forecast has been revised, underscoring that management's outlook changed during the fiscal year. The company operates as a single pharmaceutical segment, so consolidated segment-level profit diversification cannot be assessed separately. Revenue sustainability will depend on product demand, pricing, competitive dynamics and continued commercial execution, while long-term growth also depends on development productivity and regulatory outcomes.

Financial Health

Financial health is adequate, supported by ¥1,441.3bn of current assets, ¥254.3bn of cash and equivalents, and equity of ¥1,764.9bn. The current ratio is 1.09x, calculated from current assets of ¥1,441.3bn and current liabilities of ¥1,324.6bn. This is above 1.0x, so there is no immediate current-liability coverage warning, but it is below the 1.5x healthy benchmark. The quick ratio is approximately 0.84x after excluding ¥330.0bn of inventories, indicating that near-term liquidity depends partly on inventory conversion and collection of receivables. Total liabilities-to-equity, presented as D/E, are 1.04x and remain well below the 2.0x aggressive-leverage warning threshold. Interest-bearing bonds and borrowings total ¥725.3bn, equivalent to approximately 0.41x equity. The debt maturity profile shifted materially toward the short term: current bonds and borrowings increased to ¥405.3bn while non-current borrowings fell to ¥320.0bn. This partly reflects repayments of ¥62.4bn of bonds and long-term borrowings and a ¥45.3bn reduction in short-term borrowings and commercial paper in cash flow. Current assets exceed short-term bonds and borrowings, but cash plus current other financial assets of ¥277.9bn do not fully cover the ¥405.3bn current borrowing balance, making refinancing and liquidity management relevant. The equity ratio improved by 3.6 percentage points year on year to 48.9%, aided by profitability and ¥136.2bn of other comprehensive income, primarily foreign-currency translation gains. Intangible assets are substantial at ¥1,052.0bn, or 29.2% of total assets, making the balance sheet highly dependent on the recoverability of product rights and other IP. Goodwill is ¥436.1bn, equal to 24.7% of equity and 12.1% of assets, which is within the healthy goodwill-to-equity benchmark but remains material. Defined-benefit obligations of ¥23.2bn and lease payment commitments reflected in the nine-month cash flow are additional fixed obligations to monitor.

Notable B/S Changes

Bonds and borrowings—non-current: -¥244.9bn from fiscal year-end to ¥320.0bn, while current bonds and borrowings increased ¥138.7bn to ¥405.3bn; debt maturity shifted toward the short term, increasing refinancing focus. Trade and other receivables—current: +¥145.2bn to ¥777.8bn from fiscal year-end; this supported working-capital growth but consumed ¥98.0bn of operating cash flow during the nine-month period. Inventories: +¥32.7bn to ¥330.0bn from fiscal year-end; coupled with DIO of 287 days, this requires close monitoring for normalization, expiry and potential write-down risk. Cash and cash equivalents: +¥65.9bn to ¥254.3bn from fiscal year-end; strong operating cash flow exceeded investment and financing outflows. Intangible assets: -¥71.7bn to ¥1,052.0bn from fiscal year-end; despite the decline, IP assets remain 29.2% of total assets and remain central to impairment-risk assessment. Goodwill: +¥20.9bn to ¥436.1bn from fiscal year-end; goodwill remains manageable at 24.7% of equity but is material enough to warrant monitoring of acquired-business performance. Retained earnings: +¥114.1bn (+15.4%) to ¥855.0bn year on year; current-period profit more than offset dividend distributions and strengthened internal capital.

Cash Flow Quality

Cash-flow quality was strong in FY2026 Q3. Operating cash flow was ¥356.8bn, representing 1.44x net income of ¥248.0bn and comfortably exceeding the 1.0x high-quality earnings benchmark. The accruals ratio was negative 3.0%, which is consistent with favorable cash conversion rather than profit being dependent on aggressive accrual recognition. Depreciation and amortization of ¥144.2bn and impairment losses of ¥22.7bn provided significant non-cash add-backs to operating cash flow. Free cash flow was ¥310.8bn after capital expenditure of ¥41.1bn. Investing cash outflow was limited to ¥46.0bn, including ¥24.6bn of intangible-asset purchases, while other investing cash flow was positive ¥15.4bn. Inventory consumed ¥15.9bn of operating cash flow, and receivables consumed ¥98.0bn, reflecting working-capital investment alongside sales growth. Inventories increased to ¥330.0bn from ¥297.3bn at fiscal year-end, and reported DIO of 287 days is the principal quality alert. A DIO level of 287 days is far above the stated 60-90 day warning thresholds and creates risk of slow-moving stock, expiry, write-downs, or future cash conversion pressure in a pharmaceutical supply chain. The risk is particularly relevant in pharmaceuticals because regulatory inventory requirements, launch stocking and product-specific shelf-life constraints can all produce large stock balances; nevertheless, the current level warrants scrutiny of inventory composition and future write-offs. Other working-capital changes contributed a positive ¥51.9bn, helping offset the receivable and inventory cash outflows. Cash and equivalents increased by ¥65.9bn to ¥254.3bn despite ¥246.6bn of financing outflows, demonstrating that internal cash generation funded dividends, debt reduction and investment. Free cash flow presently appears sustainable, but preservation of this quality depends on collection of the larger receivable balance and stabilization of inventory days.

Dividend Sustainability

The declared Q2 dividend is ¥39 per share, and the FY2026 forecast dividend is ¥78 per share, implying an unchanged ¥39 year-end payment if achieved. Based on forecast EPS of ¥139.58, the forecast dividend payout ratio is approximately 55.9%, below the 60% sustainability benchmark. The reported interim payout ratio of 28.5% is also conservative relative to nine-month earnings. Nine-month dividends paid totaled ¥136.1bn, while free cash flow was ¥310.8bn, providing approximately 2.28x cash coverage of dividends paid. The provided FCF coverage metric of 4.40x for the interim dividend also indicates strong coverage on the stated calculation basis. Share repurchases were only ¥0.7bn during the period; therefore, total shareholder distributions were overwhelmingly dividends rather than buybacks. Including the small repurchase amount, the nine-month total return ratio remains below the dividend-only payout ratio only marginally above it and is not a material incremental capital-allocation burden. Retained earnings increased to ¥855.0bn despite the dividend payment, supported by ¥248.0bn of current-period profit. Dividend capacity is therefore solid under the current earnings and cash-flow profile. The key caveat is that earnings include a substantial year-on-year reduction in impairment charges, so future dividend growth should be assessed against recurring product cash flows, pipeline spending needs and possible IP impairments rather than the current-period profit rebound alone.

Risk Assessment

Business risks include Inventory risk is elevated: DIO of 287 days is far above the 60-90 day warning range. In pharmaceuticals, high inventories may reflect launch preparation or supply assurance, but can also lead to expiry, obsolescence, inventory write-downs and future operating-cash-flow pressure., Product-market risk remains material because revenue sustainability depends on demand, reimbursement and pricing dynamics, competitive launches, generic or biosimilar entry, and commercial execution., Pipeline and regulatory risk is inherent in the pharmaceutical model. Lower R&D intensity of 13.7% supports near-term earnings but increases the importance of successful portfolio prioritization, clinical development execution and regulatory approvals for long-term growth., The group has a single pharmaceutical operating segment, concentrating operating exposure in one industry rather than providing segment diversification., Foreign-currency exposure is material: ¥128.5bn of foreign-currency translation gains were recognized in OCI, illustrating that reported equity and comprehensive income are sensitive to exchange-rate movements..

Financial risks include Current liquidity is adequate but not abundant on a liquid-asset basis: the current ratio is 1.09x and the quick ratio is approximately 0.84x., The debt maturity profile has become more short-term weighted, with ¥405.3bn of current bonds and borrowings versus ¥320.0bn non-current. This raises refinancing and cash-management sensitivity even though overall D/E of 1.04x is not aggressive., Intangible assets represent 29.2% of total assets and goodwill represents 24.7% of equity. Recoverability assumptions for acquired IP and goodwill remain important to capital preservation., Receivables increased by ¥145.2bn from fiscal year-end and absorbed ¥98.0bn of operating cash flow, exposing future cash conversion to collection timing and credit quality..

Key concerns include Highest priority: whether the 10.2% revenue growth can persist while inventory days normalize and receivable growth moderates., High priority: the degree to which the operating-margin rebound is recurring, given that the largest year-on-year driver was the reduction in impairment and other expenses., High priority: the implied Q4 profit contribution under current guidance is low despite near-normal revenue guidance, pointing to anticipated costs or prudence that should be clarified through management commentary., Medium priority: potential impairment risk from the ¥1,052.0bn intangible-asset base if product performance, development milestones or discount-rate assumptions deteriorate., Medium priority: refinancing execution and liquidity discipline as debt balances shift from non-current to current classification..

Investment Implications

Key takeaways include Revenue growth was healthy at 10.2%, while the group returned from operating and net losses to an operating margin of 20.9% and a net margin of 15.5%., Annualized ROE of 18.7% is excellent, driven primarily by the recovery in net margin rather than elevated financial leverage., The profit rebound was materially aided by lower impairment-related and other expenses; recurring profitability should be assessed separately from this normalization effect., Operating cash flow of ¥356.8bn and free cash flow of ¥310.8bn support the credibility of current-period earnings and fully fund shareholder distributions., The inventory-days alert, receivable build and short-term debt concentration are the principal balance-sheet and cash-conversion issues to monitor., Full-year profit guidance is nearly achieved after nine months, while revenue progress is close to normal seasonality; the implied Q4 profit profile warrants attention..

Metrics to watch include Revenue growth and gross margin, currently 10.2% and 80.3%, respectively, Operating margin excluding impairment, licensing-related and other exceptional items, R&D expense and R&D intensity, currently ¥218.9bn and 13.7%, Inventory days, inventory balance and inventory write-downs, Receivable growth, collection trends and operating cash flow conversion, Intangible-asset and goodwill impairment charges, Current borrowings, refinancing activity and quick ratio, FY2026 forecast revisions and the implied Q4 operating-profit bridge, Forecast DPS of ¥78 and dividend payout ratio relative to recurring EPS and free cash flow.

Regarding relative positioning, Astellas currently exhibits strong branded-pharma-style gross profitability, excellent annualized ROE and high cash conversion. Its balance sheet is more IP-intensive than a conventional manufacturing balance sheet, with intangibles at 29.2% of assets, but goodwill-to-equity of 24.7% remains within the stated healthy range. Relative to the supplied benchmarks, profitability and cash generation are favorable, whereas inventory efficiency and near-term liquid coverage are weaker areas requiring continued scrutiny.